NASDAQ: ORKAOruka Therapeutics Inc Stock
$13.87-0.16 (-1.14%)
Updated Jan 14, 2025
ORKA Price
$13.87
Fair Value Price
N/A
Market Cap
$485.43M
52 Week Low
$13.17
52 Week High
$53.88
P/E
-2.22x
P/B
1.42x
P/S
N/A
PEG
N/A
Dividend Yield
0%
Revenue
$0.00
Earnings
-$34.40M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$40M
Beta
0.51
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ORKA Overview
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ORKA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
C
Momentum
C
Sentiment
C
Safety
D
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ORKA
Ranked#312 of 555
Ranked#312 of 555
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.69 | A | |
| $122.96 | A | |
| $5.44 | A |
Be the first to know about important ORKA news, forecast changes, insider trades & much more!
ORKA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ORKA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ORKA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ORKA is good value based on its book value relative to its share price (1.42x), compared to the US Biotechnology industry average (4.73x)
P/B vs Industry Valuation
ORKA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ORKA due diligence checks available for Premium users.
Valuation
ORKA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.22x
Industry
-107.1x
Market
30.21x
ORKA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.42x
Industry
4.73x
ORKA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ORKA's financial health
Profit margin
Revenue
$0.0
Net Income
-$28.6M
Profit Margin
0%
ORKA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$414.1M
Liabilities
$18.9M
Debt to equity
0.06
ORKA's short-term assets ($412.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ORKA's short-term assets ($412.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ORKA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ORKA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$34.9M
Investing
-$171.0k
Financing
$450.1M
ORKA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ORKA vs Biotech Stocks
Oruka Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.